Blue Jet Healthcare shares hit the 10% upper circuit after the company reported exceptional financial performance for Q3 FY25. The shares were locked at Rs 693.20.
The company’s revenue from operations soared to ₹3,184 million, marking a remarkable 90.9% year-on-year (YoY) growth. This surge in revenue underscores Blue Jet Healthcare’s ability to capitalize on market demand, particularly in its core product categories. The company’s EBITDA followed suit, rising by an impressive 127.2% YoY to reach ₹1,240 million. This growth was complemented by a substantial expansion in EBITDA margin, which improved by 630 basis points to 39.0%.
Perhaps most notably, Blue Jet Healthcare achieved its highest-ever Profit After Tax (PAT) for a quarter, posting a staggering ₹990 million. This represented a phenomenal 208.3% YoY increase in PAT, a clear testament to the company’s efficient operations and increasing market share. The PAT margin also experienced a remarkable rise, reaching 31.1% compared to 19.3% in Q3 FY24. This improvement in profitability further underscores the company’s successful cost management strategies.
For the nine months ending December 31, 2024, Blue Jet Healthcare’s total revenue reached ₹6,895 million, marking a 30.7% YoY increase. EBITDA during this period grew by 35.0% YoY, amounting to ₹2,378 million, further reinforcing the company’s upward trajectory in a competitive market.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
